Lukaszuk Krzysztof, Liss Joanna
Kliniki Endokrynologii Ginekologicznej i Leczenia Nieplodności Akademii Medycznej w Gdańsku.
Wiad Lek. 2007;60(7-8):365-70.
The presence of DNA of human papillomavirus (HPV DNA) in cervical cancers varies widely from 60 to 99%. It depends on the HPV detection method, the quality of the investigated material and the population covered. Hence, the significance of the presence of HPV DNA in the primary lesion is still under discussion. There is also a problem with HPV positive cases in histopathologically negative lymph nodes. Lymph node status is considered to be the most important prognostic factor after FIGO (International Federation of Gynecology and Obstetrics) stage. It is suggested that lymph node involvement reduces 5-year survival rate by 25 60%, within stages (except IA). However, the influence of lymph node HPV DNA positivity remains unclear. Numerous pathological parameters affecting survival rate are also recognized. Well established prognostic parameters could allow definition of the most suitable treatment. On the basis of recent results the presence of HPV DNA in lymph nodes is an early symptom of metastasis and could predict poor prognosis. We conclude that the presence of HPV DNA in lymph nodes is an early symptom of metastasis and should be treated as such in the follow up and planning the therapeutic strategy.
宫颈癌中人乳头瘤病毒DNA（HPV DNA）的存在情况差异很大，从60%到99%不等。这取决于HPV检测方法、所研究材料的质量以及所涵盖的人群。因此，HPV DNA在原发性病变中的存在意义仍在讨论中。组织病理学检查阴性的淋巴结中HPV阳性病例也存在问题。淋巴结状态被认为是国际妇产科联盟（FIGO）分期后最重要的预后因素。有人提出，在各期（IA期除外），淋巴结受累会使5年生存率降低25%至60%。然而，淋巴结HPV DNA阳性的影响仍不清楚。许多影响生存率的病理参数也已得到确认。完善的预后参数有助于确定最合适的治疗方法。根据最近的结果，淋巴结中HPV DNA的存在是转移的早期症状，可能预示预后不良。我们得出结论，淋巴结中HPV DNA的存在是转移的早期症状，在随访和制定治疗策略时应如此看待。
